Erbitux Hearing Suggests Need To Revisit Fast Track Process – Rep. Burr
Executive Summary
The Erbitux development problems suggest that the Fast Track process may not be working as well as expected, Rep. Richard Burr (R-N.C.) said during a June 13 Energy & Commerce/Oversight Subcommittee hearing on the ImClone/Bristol oncologic agent
You may also be interested in...
FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up
FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing
FDA Oncology Reviews Need Common “Best Practices” – Erbitux Follow-Up
FDA's drug and biologic centers should institute common "best practices" for oncology reviews, the Energy & Commerce Committee told the agency in a June 27 follow-up to the Erbitux hearing
Clinical Trial Oversight May Be Ongoing Theme After Erbitux Hearing
The "lack of discipline" among clinical trial investigators involved in colorectal cancer studies of ImClone/Bristol's Erbitux may suggest a need for congressional action, Rep. Ernie Fletcher (R-Ky.) said